[1] 曹磊.经皮冠状动脉介入治疗老年冠心病40例[J].中华老年学杂志,2013,33(11):2623. [2] 王安伟,罗素新,向睿.266 例冠心病患者经皮冠状动脉介入治疗的临床分析[J].重庆医学,2010,39(12):1582-1583. [3] Vera Janavel GI, Lorenzi A, Cotes C,et al. Effect of VEGF gene transfer on infarct size,left ventricular function and myocardial perfusion in sheep after two months of coronary artery occlusion[J].J Gene Med,2012,14(4):279-287. [4] 孙同文.冠状动脉旁路移植术与经皮冠状动脉介入治疗对冠心病患者远期预后影响的荟萃分析[J].中华心血管病杂志,2014,42(8):693. [5] Hibbert B, Maze R, Pourdjabbar A, et al. A comparative pharmacodynamic study of ticagrelor versus clopidogrel and ticagrelor in patients undergoing primary percutaneous coronary intervention:the CAPITAL RELOAD study[J].PLoS One,2014,9(3):e92078. [6] 陈安基,潘道波,张雄飞,等.自血回输对脊柱手术患者血清cTnI、CK-MB水平的影响[J].医学临床研究,2014,31(9):1710. [7] 王琦.经皮冠状动脉介入治疗冠心病合并心力衰竭46例临床疗效观察[J].陕西医学杂志,2012,41(4):407-408,427. [8] 董晓莉.经皮冠状动脉介入治疗老年冠心病64例临床分析[J].中国现代药物应用,2016,10(3):100-101. [9] Husted SE, Storey RF, Bliden K, et al. Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET - OFFSET and RESPOND studies[J].Clin Pharmacokinet,2012,51(6):397-409. (本文编辑:张兴珍) [收稿日期] 2017-05-15
2017, Vol. 34 
